The Effects of a Fixed Combination of Berberis aristata and Silybum marianum on Dyslipidaemia – A Meta-analysis and Systematic Review

Abstract

A fixed combination of Berberis aristata and Silybum marianum (Berberol) has been used by patients with dyslipidaemia. The aim of the present meta-analysis was to systematically evaluate the efficacy and safety of a fixed combination of B. aristata and S. marianum (Berberol) on serum lipid levels compared to placebo in a meta-analysis based on randomised, controlled trials. The meta-analysis was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement, using the PICO (patients, intervention, comparison, outcome) format, and it was registered in the International Prospective Register of Systematic Reviews. The Cochrane Central Register of Controlled Trials, PubMed, Embase, and Web of Science databases were searched for relevant studies. Placebo-controlled clinical studies involving adult patients with a condition of dyslipidaemia and receiving a fixed combination of B. aristata and S. marianum were included. Four randomised trials, including a total of 491 patients, were pooled in statistical analysis. According to the present meta-analysis, Berberol significantly lowered the low-density lipoprotein level, total cholesterol, fasting plasma glucose levels, and the Homeostatic Model Assessment index compared to placebo; however, its effects on the high-density lipoprotein level, triglyceride level, and body mass index were not statistically significant by the end of a 3-month treatment period. Berberol appeared to be safe, and it did not increase the levels of alanine transaminase, aspartate transaminase, and creatine kinase enzymes. Berberol is an effective and presumably safe complementary therapy for the treatment of dyslipidaemia; however, the evidence supporting its use is very limited. The optimum dose and duration of treatment are unclear. A comprehensive evaluation of efficacy and safety is required in further high-quality clinical studies involving larger patient populations.

Key words

silymarin - Silybum marianum - Compositae - berberine - Berberis aristata - Berberidaceae - dyslipidaemia - meta-analysis

• References

• 1 Houston M. Dyslipidemia. In: Rakel D. ed. Integrative Medicine. Philadelphia, PA: Elsevier; 2018: 264-275e5
• 2 McEvoy JW, Whelton SP, Blumenthal RS. Dyslipidemia. In: Bakris GL, Sorrentino M. eds. Hypertension: A Companion to Braunwaldʼs Heart Disease. Philadelphia: Elsevier; 2018: 353-360
• 3 Poli A, Visioli F. Pharmacology of nutraceuticals with lipid lowering properties. High Blood Press Cardiovasc Prev 2019; 26: 113-118
• 4 Di Pierro F, Bellone I, Rapacioli G, Putignano P. Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins. Diabetes Metab Syndr Obes 2015; 8: 89-96
• 5 Potdar D, Hirwani RR, Dhulap S. Phyto-chemical and pharmacological applications of Berberis aristata . Fitoterapia 2012; 83: 817-830
• 6 Feng X, Sureda A, Jafari S, Memariani Z, Tewari D, Annunziata G, Barrea L, Hassan STS, Šmejkal K, Malaník M, Sychrová A, Barreca D, Ziberna L, Mahomoodally MF, Zengin G, Xu S, Nabavi SM, Shen AZ. Berberine in cardiovascular and metabolic diseases: from mechanisms to therapeutics. Theranostics 2019; 9: 1923-1951
• 7 Ju J, Li J, Lin Q, Xu H. Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials. Phytomedicine 2018; 50: 25-34
• 8 Pan G, Wang G, Liu X, Fawcett JP, Xie Y. The involvement of P-glycoprotein in berberine absorption. Pharmacol Toxicol 2002; 91: 193-197
• 9 Hadi A, Pourmasoumi M, Mohammadi H, Symonds M, Miraghajani M. The effects of silymarin supplementation on metabolic status and oxidative stress in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of clinical trials. Complement Ther Med 2018; 41: 311-319
• 10 Soo YC, Min KS, Na HK, Jung OJ, Eun JG, Hwa JL. Inhibition of P-glycoprotein by natural products in human breast cancer cells. Arch Pharm Res 2005; 28: 823-828
• 11 Ferreira A, Rodrigues M, Meirinho S, Fortuna A, Falcão A, Alves G. Silymarin as a flavonoid-type P-glycoprotein inhibitor with impact on the pharmacokinetics of carbamazepine, oxcarbazepine and phenytoin in rats. Drug Chem Toxicol 2019; 25: 1-12 doi:10.1080/01480545.2019.1601736
• 12 Guarino G, Strollo F, Carbone L, Della Corte T, Letizia M, Marino G, Gentile S. Bioimpedance analysis, metabolic effects and safety of the association berberis aristataisilybum marianum: a 52-week double-blind, placebo-controlled study in obese patients with type 2 diabetes. J Biol Regul Homeost Agents 2017; 31: 495-502
• 13 Guarino G, Della Corte T, Sofia M, Carbone L, Marino G, Gentile S. Effetti metabolici dellʼassociazione berberina-silimarina vs. placebo in diabetici tipo 2 obesi, ipercolesterolemici. G di ADM 2015; 18: 188-191
• 14 Derosa G, DʼAngelo A, Maffioli P. The role of a fixed Berberis aristata/Silybum marianum combination in the treatment of type 1 diabetes mellitus. Clin Nutr 2016; 35: 1091-1095
• 15 di Pierro F, Villanova N, Agostini F, Marzocchi R, Soverini V, Marchesini G. Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control. Diabetes Metab Syndr Obes 2012; 5: 213-217
• 16 Di Pierro F, Putignano P, Villanova N, Montesi L, Moscatiello S, Marchesini G. Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetes. Clin Pharmacol Adv Appl 2013; 5: 167-174
• 17 Derosa G, Bonaventura A, Bianchi L, Romano D, DʼAngelo A, Fogari E, Maffioli P. Berberis aristata/Silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients. Expert Opin Biol Ther 2013; 13: 1495-1506
• 18 Derosa G, Bonaventura A, Bianchi L, Romano D, DʼAngelo A, Fogari E, Maffioli P. Effects of Berberis aristata/Silybum marianum association on metabolic parameters and adipocytokines in overweight dyslipidemic patients. J Biol Regul Homeost Agents 2013; 27: 717-728
• 19 Derosa G, Romano D, DʼAngelo A, Maffioli P. Berberis aristata combined with Silybum marianum on lipid profile in patients not tolerating statins at high doses. Atherosclerosis 2015; 239: 87-92
• 20 Derosa G, Romano D, DʼAngelo A, Maffioli P. Berberis aristata/Silybum marianum fixed combination (Berberol^®) effects on lipid profile in dyslipidemic patients intolerant to statins at high dosages: a randomized, placebo-controlled, clinical trial. Phytomedicine 2015; 22: 231-237
• 21 Bahmani M, Shirzad H, Rafieian S, Rafieian-Kopaei M. Silybum marianum: Beyond hepatoprotection. J Evid Based Complementary Altern Med 2015; 20: 292-301
• 22 Soleimani V, Delghandi PS, Moallem SA, Karimi G. Safety and toxicity of silymarin, the major constituent of milk thistle extract: An updated review. Phyther Res 2019; 33: 1-12
• 23 Lan J, Zhao Y, Dong F, Yan Z, Zheng W, Fan J, Sun G. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol 2015; 161: 69-81
• 24 Vahabzadeh M, Amiri N, Karimi G. Effects of silymarin on metabolic syndrome: a review. J Sci Food Agric 2018; 98: 4816-4823
• 25 Fogacci F, Grassi D, Rizzo M, Cicero AFG. Metabolic effect of berberine–silymarin association: A meta-analysis of randomized, double-blind, placebo-controlled clinical trials. Phyther Res 2019; 33: 862-870
• 26 Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560
• 27 Cochran WG. The combination of estimates from different experiments. Biometrics 1954; 10: 101-129
• 28 Higgins JPT, Green S, Chandler J, Cumpston M, Li T, Page M, Welch V. eds. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 [updated March 2011] [Internet]. The Cochrane Collaboration. Available at: http://www.handbook.cochrane.org Accessed February 26, 2018
• 29 Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ. GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924-926